A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

NCT01624259 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of two diabetes medications, dulaglutide and liraglutide, in adults with type 2 diabetes over a 26-week period.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 599 people

Who can join Ages 18+ · all sexes

Timeline Started 2012-06 · est. completion 2013-11

Where 57 sites · Czechia, Germany, Hungary, Mexico, Poland, Puerto Rico, Romania, Slovakia, Spain, United States

What this study is testing ClinicalTrials.gov NCT01624259 ↗

Description as written by the study sponsor.

The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.

Treatments tested

LY2189265 also known as Dulaglutide Drug

Administered SC
Liraglutide Drug

Administered SC
Metformin Drug

Main thing measured	Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	liraglutide, dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01624259 ↗